+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Synjardy"

Diabetic Gastroparesis Treatment Global Market Report 2024 - Product Thumbnail Image

Diabetic Gastroparesis Treatment Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 500 Pages
  • United States
From
From
Jardiance - Product Thumbnail Image

Jardiance

  • Drug Pipelines
  • February 2019
  • 43 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Synjardy is a brand of endocrine and metabolic disorder drugs used to treat type 2 diabetes. It is a combination of empagliflozin and metformin, two drugs that work together to reduce blood sugar levels. Synjardy is taken orally and works by increasing the amount of glucose that is removed from the blood and decreasing the amount of glucose that is produced by the liver. It also helps to reduce the amount of glucose that is absorbed from food. Synjardy is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. The Synjardy market is highly competitive, with many companies offering similar products. Some of the major players in the market include Boehringer Ingelheim, Merck & Co., Sanofi, Novo Nordisk, and Eli Lilly. Other companies in the market include AstraZeneca, GlaxoSmithKline, and Takeda Pharmaceuticals. Show Less Read more